Longevity · Epigenetic clocks · Aging Cell
Bonn team resets epigenetic age by about 60 years during direct blood-to-neural stem cell conversion (Aging Cell / University Hospital Bonn)
Directly reprogramming erythroid precursors into induced neural stem cells, without a pluripotent stage, gradually reset epigenetic clocks over roughly 50+ days; cells from an 80-year-old reached a molecular age under 20. The slow reset gives a window to study which factors speed or slow rejuvenation, relevant to neurodegeneration risk. Berg et al., “Protracted Fate Acquisition and Epigenetic De-Aging During Induced Neural Stem Cell Conversion of Human Blood Cells.”
Caveat: In vitro only; a model for mechanism research, not a therapy or human treatment claim.
Bionity / University Hospital Bonn →
Gene editing · Metabolic disease · Beam Therapeutics
BEAM-301 base editing restores fasting endurance in GSDIa Phase 1/2 (Beam Therapeutics, Oct 13)
Initial data in 6 patients with G6PC1 R83C GSDIa after a single IV LNP base-editor infusion: by Day 36 both evaluable 40 mg patients reached the protocol maximum of at least 15 hours of controlled fasting (baseline median about 2.5 hours), with large cuts in daily starch needs. Safety was broadly consistent with LNP therapies, including Grade 3 infusion reactions that resolved; steroid premedication has been optimized.
Caveat: Company-reported initial Phase 1/2; small n; short follow-up in the 40 mg cohort; ESGCT poster still ahead (Oct 28); not approved.
Beam press release (Stockhouse) →
Gene editing · Progeria · Science Advances
Adenine base editing corrects LMNA in a trilayer progeria vessel model (Science Advances / Duke)
Adding adventitial fibroblasts to tissue-engineered blood vessels amplified HGPS vascular pathology. Adenine base editing corrected about 89–90% of cells, eliminated detectable progerin, and largely restored inflammation, calcification, stiffness and smooth-muscle-cell density, though some transcriptional and heterochromatin defects remained.
Caveat: Preclinical tissue-engineered vessels; lentiviral delivery in vitro; not a clinical therapy.
CRISPR Medicine News →
Genes & disease · Alzheimer’s · Nature Aging
Brain DNA methylation partly mediates the APOE link to Alzheimer neuropathology (Nature Aging, Oct 12)
An EPIC v2 EWAS in 1,250 Rush prefrontal cortex samples found 107 AD-pathology methylation sites (38 replicated in the Netherlands Brain Bank, n=139). A methylation score from APOE-associated sites mediated about 8.6% of APOE’s effect on neuropathologic AD diagnosis, and single-nucleus RNA-seq tied several genes (e.g. RIN3, LGMN) to neuron vs glia expression shifts.
Caveat: Bulk postmortem cortex; cross-sectional, so cause vs consequence is unclear; mediation not validated in other cohorts with APOE genotypes.
Nature Aging →
Gene therapy · Retina · AAO 2026
Laru-zova pivotal VISTA: first XLRP gene-therapy trial to meet the FDA-endorsed LLVA primary endpoint (Beacon, AAO Retina Subspecialty Day)
In 85 males with RPGR-XLRP, at least 15-letter low-luminance visual acuity responders at Month 12 were 31.0% on high dose (p=0.0019), 24.1% on low dose (p=0.0106) and 0% in untreated controls, with supportive microperimetry trends. Adverse events were largely procedure-related and mild or moderate.
Caveat: Company-presented pivotal data; investigational, not FDA-approved; rolling BLA planned later this year per the company.
Syncona / Beacon Therapeutics →
